Keywords: b-ms/karo, bio, drop, obesity, drug, bristol-myers, squibb

B-MS/Karo Bio drop obesity drug

Article | 01 April 2002

Bristol-Myers Squibb has discontinued the development of a thyroidhormone receptor modulator for obesity, derived from its joint research program with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bristol-Myers Squibb

Go to company listing